[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360701-105":59,"doc-detail-360701-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","distinct-molecular-and-clinical-aggressiveness-in-very-early-onset-metastatic-colorectal-cancer-survival-and-genomic-divergence-between-patients-aged-30-39-versus-40-49-years","Distinct molecular and clinical aggressiveness in very early-onset metastatic colorectal cancer: survival and genomic divergence between patients aged 30-39 versus 40-49 years","","Early-onset colorectal cancer (EOCRC) is rising worldwide and shows clinical heterogeneity. This study tests whether very early-onset metastatic colorectal cancer (VEOCRC, ages 30-39) has distinct clinical and genomic characteristics compared with EOCRC in patients aged 40-49, and whether these differences alter survival after metastatic diagnosis. Multi-institutional data were analyzed using Kaplan-Meier survival estimates, Cox hazard ratios, and odds-ratio comparisons of genomic alterations obtained by FoundationOne next-generation sequencing.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/distinct-molecular-and-clinical-aggressiveness-in-very-early-onset-metastatic-colorectal-cancer-survival-and-genomic-divergence-between-patients-aged-30-39-versus-40-49-years/360701/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/distinct-molecular-and-clinical-aggressiveness-in-very-early-onset-metastatic-colorectal-cancer-survival-and-genomic-divergence-between-patients-aged-30-39-versus-40-49-years/360701.png","ImageObject",300,407,{"name":92,"@type":93},"Aldword","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study question about very early-onset metastatic colorectal cancer?","Question",{"text":112,"@type":113},"The study evaluates whether patients aged 30-39 (VEOCRC) have specific clinical and genomic features compared with patients aged 40-49 within EOCRC, and whether these differences affect survival after metastatic diagnosis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were survival outcomes and risk estimates analyzed?",{"text":117,"@type":113},"Overall survival from metastatic diagnosis was estimated using Kaplan-Meier methods, and hazard ratios were calculated with Cox regression.",{"name":119,"@type":110,"acceptedAnswer":120},"Which genomic and clinical differences were found between age groups?",{"text":121,"@type":113},"Patients aged 30-39 had shorter median overall survival and a genomic profile marked by higher KRAS mutation rates and fewer APC alterations, along with more frequent peritoneal metastases and a higher proportion of ECOG PS 0.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360701,1790468552,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},2336478940917,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","ORIGINAL ARTICLE  \nDistinct molecular and clinical aggressiveness in very early-onset metastatic colorectal cancer: survival and genomic divergence between patients aged 30-39 versus 40-49 years  \nA. Pretta1 ∗, G. Rebecchi2, G. Maddalena3, F. Marmorino4 , 5, P. Ziranu1, F. Manoni2, M. C. De Grandis3, M. Carullo4 , 5,  \nP. A. Ferrari6, C. Donisi1, G. Randon2, E. Perissinotto3, A. Taravella4 , 5, V. Nasca2, F. Buggin3, G. Pretta7, P. Ciracì4 , 5,  \nF. Bergamo3, C. Cremolini4 , 5, S. Lonardi3, M. Scartozzi1† & F. Pietrantonio2†  \n1Department of Medical Sciences and Public Health, Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari; 2Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; 3Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS, Padua; 4Unit of Oncology, Azienda OspedalieroUniversitaria Pisana, Pisa; 5Department of Translational Research & New Technologies in Medicine & Surgery, University of Pisa, Pisa; 6Department of Thoracic Surgery, Thoracic Surgery and Interventional Bronchoscopy Unit, A. R. N.A.S.“G. Brotzu”, Cagliari, Italy; 7Science Department, King’s School Hove, Brighton and Hove, UK  \nAvailable online xxx  \nBackground: Early-onset colorectal cancer (EOCRC) is increasing worldwide and exhibits clinical heterogeneity. Patients younger than 40 years may constitute a biologically distinct subgroup within EOCRC. We investigated whether ‘very early-onset’ metastatic colorectal cancer (VEOCRC, ages 30-39) exhibits specific clinical and genomic features compared with EOCRC in patients aged 40-49 and whether these differences lead to variations in survival from the time of metastatic diagnosis.  \nMaterials and methods: We analysed the data of metastatic EOCRC patients in a multi-institutional database, divided into two predefined age groups: 30-39 years and 40-49 years. Overall survival (OS) from metastatic diagnosis was estimated using Kaplan—Meier methods, and hazard ratios (HRs) were calculated with Cox regression. Comprehensive genomic profiling was carried out using the Foundation Medicine next-generation sequencing platform (FoundationOne®) . Key molecular alterations were compared using odds ratios (ORs) . Baseline clinicopathologic characteristics were assessed using χ2 or two-sided Fisher’s exact tests.  \nResults: A total of 264 patients were included (aged 30-39: n = 65; aged 40-49: n = 199) . Median OS was shorter inpatients aged 30-39 years than in those aged 40-49 years (30 .0 versus 38.0 months; log-rank P = 0.0269; HR 0.67) . A distinct genomic profile appeared in patients with VEOCRC, characterised by higher KRAS mutation rates (55 .4% versus 42.0%; OR 1.71; one-sided P = 0.041) and fewer APC alterations (69 . 2% versus 82.0%; one-sided P = 0.024) . NRAS, BRAF, PTEN, and POLE alterations were directionally consistent with a more aggressive biology, although event counts were limited. Clinically, overall Eastern Cooperative Oncology Group performance status (ECOG PS) distribution was similar (χ2 P = 0.099), but ECOG PS 0 was more common in VEOCRC (89 . 1% versus 76.8%; P = 0.0468) . Peritoneal metastases occurred significantly more frequently in patients aged 30-39 (32 .3% versus 19.6%; P = 0.041) . No differences were observed regarding liver, lung, or nodal involvement.  \nConclusions: Patients aged 30-39 years constitute a biologically distinct subgroup within EOCRC, with shorter survival, KRAS mutation enrichment, fewer APC alterations, and increased peritoneal involvement. These findings support the emerging idea of an ‘ultra-young’, genomically driven CRC subtype, with implications for disease biology, risk assessment, and treatment development.  \nKey words: early-onset colorectal cancer, metastatic colorectal cancer, molecular profiling, next-generation sequencing, precision oncology  \n*Correspondence to: Dr Andrea Pretta, Medical Oncology Unit, University Hospital and University of Cagliari, SS 554 Bivio per Sestu, Monserrato 09042, Cagliari","cbCaib4cDKfMUpbd","https://ap.wps.com/l/cbCaib4cDKfMUpbd","pdf",764451,"English","# Background\n# Materials and methods\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"What is the study question about very early-onset metastatic colorectal cancer?\",\"answer\":\"The study evaluates whether patients aged 30-39 (VEOCRC) have specific clinical and genomic features compared with patients aged 40-49 within EOCRC, and whether these differences affect survival after metastatic diagnosis.\"},{\"question\":\"How were survival outcomes and risk estimates analyzed?\",\"answer\":\"Overall survival from metastatic diagnosis was estimated using Kaplan-Meier methods, and hazard ratios were calculated with Cox regression.\"},{\"question\":\"Which genomic and clinical differences were found between age groups?\",\"answer\":\"Patients aged 30-39 had shorter median overall survival and a genomic profile marked by higher KRAS mutation rates and fewer APC alterations, along with more frequent peritoneal metastases and a higher proportion of ECOG PS 0.\"}]","Distinct molecular and clinical aggressiveness in very early-onset metastatic colorectal cancer: survival and genomic divergence between patients aged 30-39 versus 40-49 years | PDF",1790141250,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/345fa7337524d0e68a743102e840930e.webp",983,1269,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e9b50be610715095c65abc1d5d1653d1.webp",982,1268,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b553f4af6889cc5b401c9a69360e1a9d.webp",981,1266,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dda8df1e1e5e658c8c526b329b4e68b5.webp",980,1265]